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Background. Scabies is a public health problem in many countries, with impetigo and its complications important conse-
quences. Ivermectin based mass drug administration (MDA) reduces the prevalence of scabies and, to a lesser extent, impetigo. We 
studied the impact of co-administering azithromycin on the prevalence of impetigo and antimicrobial resistance.
Methods. Six communities were randomized to receive either ivermectin-based MDA or ivermectin-based MDA co-adminis-
tered with azithromycin. We measured scabies and impetigo prevalence at baseline and 12 months. We collected impetigo lesions 
swabs at baseline, 3 and 12 months to detect antimicrobial resistance.
Results. At baseline, scabies and impetigo prevalences were 11.8% and 10.1% in the ivermectin-only arm and 9.2% and 12.1% in 
the combined treatment arm. At 12 months, the prevalences had fallen to 1.0% and 2.5% in the ivermectin-only arm and 0.7% and 
3.3% in the combined treatment arm. The proportion of impetigo lesions containing Staphylococcus aureus detected did not change 
(80% at baseline vs 86% at 12 months; no significant difference between arms) but the proportion containing pyogenic streptococci 
fell significantly (63% vs 23%, P < .01). At 3 months, 53% (8/15) of S. aureus isolates were macrolide-resistant in the combined treat-
ment arm, but no resistant strains (0/13) were detected at 12 months.
Conclusions. Co-administration of azithromycin with ivermectin led to similar decreases in scabies and impetigo prevalence 
compared to ivermectin alone. The proportion of impetigo lesions containing pyogenic streptococci declined following MDA. There 
was a transient increase in the proportion of macrolide-resistant S. aureus strains following azithromycin MDA.
Clinical Trials Registration. clinicaltrials.gov (NCT02775617).
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Scabies is a major public health problem in many tropical 
countries [1]. As well as the direct consequences of infestation, 
scabies leads to an increased risk of secondary bacterial skin 
disease (impetigo), mostly due to Staphylococcus aureus and 
Streptococcus pyogenes [2], due to breaks in the skin and pos-
sibly down-regulation of complement by Sarcoptes scabei [3]. 
Skin infections, especially those due to S. pyogenes, can result 
in more serious disease, including bacteremia, glomerulone-
phritis, and possibly rheumatic heart disease [1, 4–6]. In 2017 
scabies was formally recognized as a neglected tropical disease 
(NTD) by the World Health Organization (WHO), leading to 
increased interest in strategies for controlling scabies and its 
associated morbidity.
Mass drug administration (MDA) has been demonstrated to 
be effective as a control measure for scabies, through single-arm 
studies using permethrin or ivermectin [7–10] and, recently, a 
comparative trial in Fiji, which demonstrated ivermectin was 
superior to permethrin [11]. In these studies, community-wide 
treatment for scabies, without antibacterial therapy, led to sub-
stantial reductions in impetigo.
Given the ongoing burden of impetigo and its complications 
in these settings, it is reasonable to consider whether the addi-
tion of an antibacterial agent may be beneficial. The macrolide 
azithromycin is a potential candidate for this role, because it has 
good activity against S. pyogenes and S. aureus. Because of its 
long half-life and low toxicity, it is recommended by WHO for 
mass drug administration for control of trachoma, and eradica-
tion of yaws [12, 13].
Any benefit from community-wide use of antimicrobial 
agents needs to be weighed against the risk of promoting the 
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selection of antimicrobial resistant organisms. A  number of 
studies have assessed the impact of azithromycin MDA on 
nasopharyngeal or oropharyngeal carriage of azithromycin 
resistant bacteria [14–18], but none have assessed the impact 
on organisms isolated from impetigo lesions.
As in many Pacific Island nations, the prevalence of 
scabies and impetigo is high in the Solomon Islands 
[7, 19–21]. Yaws and trachoma have also been found at high 
levels in the Solomon Islands [22–24]. This co-endemicity 
has provided a rationale to consider co-administration of 
ivermectin and azithromycin. Previous studies suggest that 
co-administration is safe compared to individual use of the 
2 agents [25, 26].
We conducted a community randomised trial to assess 
whether adding azithromycin to ivermectin-based MDA for 
scabies had an additional impact on the prevalence of impetigo 
at 12 months or on antimicrobial resistance of Gram-positive 
bacteria isolated from impetigo lesions.
METHODS
Study Setting and Recruitment
This was a community randomised open label study conducted 
in Malaita province of the Solomon Islands. Six communities 
were randomized to one of 2 arms: an ivermectin arm or a com-
bined-treatment arm. We selected communities that were iso-
lated from each other to reduce contamination between the 2 
study arms.
All residents living in selected communities were eligible to 
participate. Community engagement and education were con-
ducted by the study team prior to commencement of the study. 
Written informed consent was obtained from adults and from 
the parent or guardian of children. Assent was also obtained 
from children who were able to provide it.
Data Collection
Study visits took place at 3 timepoints. At baseline, participants 
were seen for enrollment, initial data collection and treatment. 
At 3 months, we reexamined children (aged ≤12 years) in each 
community to allow for collection of swabs to monitor for anti-
microbial resistance (see below); this age group was selected as 
they were anticipated to have the highest prevalence of impetigo. 
At the 12-month follow-up visit, we again aimed to examine all 
participating residents in participating communities. Prior to 
visits at both baseline and 12 months, the study team conducted 
a village census. At baseline and 12 months, participants under-
went a standardized examination by an experienced clinician 
(MM) with data recorded on the presence or absence of any 
skin lesions, their location, and whether they were consistent 
with scabies, impetigo, or another diagnosis. The clinical diag-
nosis of scabies was based on the morphology (burrows, pap-
ules, nodules, vesicles) and distribution of rash alongside the 
presence of pruritus or evidence of excoriation. Active impetigo 
was diagnosed on the basis of discrete papular, pustular, or 
ulcerative lesions with associated erythema, crusting, bullae, or 
frank pus [27]. The severity of scabies and impetigo was classi-
fied as previously described [19]. Data were collected directly 
into Android smartphones using the OpenDataKit software 
package [28].
Treatment
Treatment was offered to all participating members of the 
community and was directly observed by the study team. In 
the ivermectin arm we administered ivermectin MDA at base-
line. In the combined treatment arm we co-administered iver-
mectin and azithromycin MDA at baseline. Ivermectin MDA 
consisted of a single oral dose of ivermectin (200 μg/kg) deter-
mined by body weight. In individuals with a contra-indica-
tion to ivermectin (pregnancy, breast-feeding, weight <15 kg) 
topical permethrin was offered instead. Individuals clinically 
diagnosed with scabies at baseline were offered a second dose 
of ivermectin (or second application of topical permethrin) at 
7 days [11]. Azithromycin MDA consisted of a single oral dose 
of azithromycin (30  mg/kg, max 2 gm) determined by body 
weight [29, 30]
Sample Collection and Analysis
To assess changes in antimicrobial resistance, we aimed to col-
lect swabs from approximately 40 active impetigo lesions in 
children (≤12 years) per treatment arm at baseline (equivalent 
to approximately one third of our anticipated cases of impe-
tigo at baseline). At 3 months, swabs were collected from all 
children with active impetigo. Finally, at 12 months we again 
aimed to collect swabs from all individuals with active impe-
tigo. We collected swabs from a single lesion in each individual. 
A sterile cotton-tipped swab was rolled across pus or exudate 
from active impetigo lesions and placed inside a dry-transport 
tube, then shipped at ambient temperature within 7 days [31]. 
Swabs were sent to the Murdoch Children’s Research Institute, 
Melbourne, Australia, where they were streaked onto horse 
blood agar plates and incubated at 37° C in 5% CO2. Plates 
were reviewed at 24 hours and purity plating performed. 
Beta-hemolytic streptococcal colonies were grouped by latex 
agglutination (Pro-Lab Diagnostics, Richmond Hill, Canada). 
S. aureus colonies were detected using a latex slide agglutina-
tion test (Oxoid, United Kingdom). Antimicrobial sensitiv-
ity testing was performed using VITEK 2 (bioMérieux Inc., 
Durham, NC). We inferred azithromycin resistance from the 
results of erythromycin sensitivity testing using breakpoints 
defined by the Clinical and Laboratory Standards Institute 
[32]. We report sensitivity results for (1) S. aureus and (2) pyo-
genic streptococci (groups A, C, and G) collectively, including 
S. pyogenes (group A).
Emm-typing was performed according to the protocol spec-
ified by the Centers for Disease Control and Prevention with 
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minor modifications, as previously described [33]. Emm-
clusters were deduced based on the emm-typing results [34].
Statistical Analysis
The study was designed to assess whether adding a single 
oral dose of azithromycin, alongside ivermectin, resulted in a 
decrease in the prevalence of impetigo at 12 months compared 
to treatment with ivermectin alone. We calculated the preva-
lence of scabies and impetigo in each study arm at baseline 
and 12 months. We calculated the absolute and relative reduc-
tion in scabies and impetigo prevalence between baseline and 
12 months. We compared the change in prevalence, separately 
for scabies and impetigo, between study groups by calculat-
ing the ratio of the prevalence at baseline and 12 months for 
each group, and testing the hypothesis that these 2 ratios were 
equal [35].
Sample Size Calculations
We estimated the pre-MDA prevalence of scabies and impetigo 
to be approximately 15% and 25% respectively. Based on pre-
vious studies, we anticipated the prevalence of scabies would 
fall to 1% in both arms and the prevalence of impetigo would 
fall to 10% at 12 months in the ivermectin-only arm [11, 19]. 
Assuming that in the combined-treatment arm impetigo prev-
alence fell to 5%, and loss-to-follow-up was 10%, we needed to 
enroll 635 individuals in each study arm to have 80% power to 
detect a difference between study arms as significant at the 0.05 
level. As a secondary outcome we calculated the proportion of 
S. aureus and S. pyogenes isolates which were macrolide resis-
tant in each arm at baseline, 3 months and 12 months. Statistical 
analysis was conducted in R 3.4.2 [36].
Ethics Approval
The study was approved by the London School of Hygiene & 
Tropical Medicine, the Solomon Islands National Health Ethics 
Committee and the Atoifi Adventist Hospital Ethics Committee. 
Azithromycin was provided by WHO (who purchased it from 
Medopharm [India]). Ivermectin was purchased from Merck 
Sharp and Dohme (Australia). Permethrin was purchased from 
Pharmatec (Fiji). At 12 months, all individuals in the ivermec-
tin-only arm were offered azithromycin in line with WHO 
guidelines for the treatment of yaws [13]. The study was pro-
spectively registered on clinicaltrials.gov (NCT02775617). All 
authors had access to study data and shared responsibility for 
the decision to submit for publication.
RESULTS
At baseline, 1291 individuals (90.8% of the resident population 
in the 6 study communities) were examined and received treat-
ment. At the 12-month follow-up the resident population of the 
study communities had decreased to 1255, of whom 1083 indi-
viduals were examined (86.3%) (Table 1). Follow-up was lower 
in the ivermectin-only arm at 12  months (ivermectin-only 
76.2% vs combined treatment arm 96.3%). Overall, 46.6% of 
participants were male, and the median age of participants was 
25 years (IQR 11–47) (Table 1).
At baseline the prevalence of scabies was 11.8% (95% con-
fidence interval [CI] 9.4–14.6%) in the ivermectin-only arm 
and 9.2% (95% CI 7.1–11.7%) in the combined-treatment 
arm. The severity of scabies was similar in both arms; overall, 
77.8% of individuals had mild scabies, 20% had moderate sca-
bies, and 2.2% had severe scabies (data not shown). No cases 
of crusted scabies were detected. At baseline the prevalence of 
active impetigo was 10.1% (95% CI 8.1–13.0%) in the ivermec-
tin-only treatment arm and 12.1% (95% CI 9.7–14.9%) in the 
combined-treatment arm. The severity of impetigo was similar 
in both groups; overall, 84.1% of participants had mild impe-
tigo, 11% had moderate impetigo, and 4.9% had severe impe-
tigo (data not shown).
At 12  months the prevalence of scabies and impetigo had 
fallen to 1.0% (95% CI 0.3–2.6%) and 2.5% (95% CI 1.4–4.5%), 
respectively, in the ivermectin-only treatment arm and to 0.7% 
(95% CI 0.2–1.8%) and 3.3% (95% CI 2.1–5.1%), respectively, in 
the combined treatment arms (Table 2). There was no significant 
difference between the two groups (91.5% vs 92.4%, P = .31), in 
the change from baseline to 12 months in scabies prevalence or 
the change in impetigo prevalence (75.2% vs 72.7%, P = .49).
We performed a post hoc sensitivity analysis to assess 
whether the lower follow-up in the ivermectin-only arm 
might have affected our results. We calculated the prevalence 
of impetigo that would have been seen in the ivermectin-only 
treatment arm if we had achieved a follow-up at a level simi-
lar to the combined treatment arm and the prevalence amongst 
participants not seen at 12 months had been unchanged from 
baseline. Under these assumptions, the prevalence of impetigo 
Table 1. Demographics
Ivermectin Only Arm Combined Treatment Arm
Baseline 12 Months Follow-up Baseline 12 Months Follow-up
Resident population 717 627 705 628
Enrolled population (%) 638 (88.9%) 478 (76.2%) 653 (92.6%) 605 (96.3%)
Median age [inter-quartile range] (years) 25 [12–47] 25 [10–47] 24 [10–45] 26 [12–47]
Sex (male) (%) 326 (51.1%) 212 (44.4%) 318 (48.7%) 297 (49.1%)
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in the ivermectin-only treatment arm would have been 4.1% at 
twelve months. In this analysis there was no significant differ-
ence in the relative reduction in impetigo between arms (60.2% 
vs 72.7%, P = .23).
Swabs were collected from 73 people with impetigo at base-
line, 36 people at 3  months, and 22 people at 12  months. At 
baseline, 80% of impetigo lesions from which we obtained a 
swab yielded S.  aureus on culture and 62% yielded pyogenic 
streptococci (predominantly S.  pyogenes, 56%). At 3 and 
12  months the proportion of S.  aureus was unchanged (78% 
and 86%, respectively), but the proportion of impetigo lesions 
from which S. pyogenes were cultured had fallen significantly to 
33% at 3 months (P = .04 for the comparison to baseline) and 
23% at 12 months (P < .01 for the comparison to baseline). The 
relative decrease in S. pyogenes was similar in both arms of the 
study (Table 3).
No macrolide resistance was detected among streptococci in 
either arm at any of the 3 time points. In the ivermectin-only 
treatment arm we did not isolate any macrolide-resistant 
S. aureus at any time point. In the combined-treatment arm, one 
isolate of S. aureus was macrolide-resistant at baseline, and 8/15 
(53%) of S. aureus isolates were macrolide-resistant at 3 months. 
At 12 months, no macrolide-resistance was detected in any of 
the 6 isolates tested (Table  4). Isolates of S.  pyogenes fell into 
27 different emm-types. Twenty-five emm-types could be cat-
egorized into one of 11 different emm-clusters (Supplementary 
Table 1).
CONCLUSION
In the first study to directly compare co-administration of azi-
thromycin and ivermectin with ivermectin-only MDA, co-ad-
ministration did not result in a greater decrease in the clinical 
prevalence of impetigo at 12 months, compared to ivermectin 
alone. Substantial decreases were observed in both the preva-
lence of scabies and impetigo, but the magnitude of the decrease 
was similar in the 2 study arms and consistent with the effect 
size seen in previous studies [11]. In both arms, we observed 
a large reduction in the proportion of impetigo lesions from 
Table 3. Impetigo Culture Results
Baseline 3 Months 12 Months
Organism Isolated
(%, 95% CI)
Organism Isolated
(%, 95% CI)
Organism Isolated
(%, 95% CI)
Ivermectin only Staphylococcus aureus 27/35
(77%, 59–89%)
13/19
(68%, 43–86%)
6/6
(100%, 52–100%)
Pyogenic streptococcia 28/35b
(80%, 63–91%)
9/19c
(47%, 25–71%)
1/6
(17%, 9–64%)
Combined treatment Staphylococcus aureus 32/38
(84%, 68–93%)
15/17
(88%, 62–98%)
13/16
(81%,54–95%)
Pyogenic streptococcia 17/38b
(45%, 29–63%)
5/17c
(29%, 11–56%)
4/16
(25%, 8–53%)
Total Staphylococcus aureus 59/73
(81%, 70–89%)
28/36
(78%, 60–89%)
19/22
(86%, 64–96%)
Pyogenic streptococcia 45/73
(62%, 49–73%)
14/36
(39%, 24–56%)
5/22
(23%, 9–46%)
Abbreviation: CI, confidence interval.
aFor simplicity we report Group C/G streptococci alongside Streptococcus pyogenes.
bOne group C/G streptococcus in the ivermectin-only treatment arm and 4 in the combined treatment arm.
cTwo group C/G streptococcus in the ivermectin-only treatment arm.
Table 2. Prevalence of Scabies and Impetigo
Baseline 12 Months Absolute Reduction Relative Reduction
Ivermectin only Scabies 11.8%
(95% CI 9.4–14.6%)
(n = 75/638)
1.0%
(95% CI 0.3–2.6%)
(n = 5/478)
10.8%
 (95% CI 8.0–13.4%)
91.5%
(95% CI 68.5–100%)
Impetigo 10.1%
 (95% CI 8.1–13.0%)
(n = 66/638)
2.5%
(95% CI 1.4–4.5%)
(n = 12/478)
7.6%
(95% CI 5.1–10.6%)
75.2%
 (95% CI 67.9–100%)
Combined treatment Scabies 9.2%
(95% CI 7.1–11.7%)
(n = 60/653)
0.7%
(95% CI 0.2–1.8%)
(n = 4/605)
8.5%
(95% CI 6.2–10.8%)
92.4%
(95% CI 49.2–100%)
Impetigo 12.1% (95% CI 9.7%–14.9)
(n = 79/653)
3.3%
(95% CI 2.1–5.1%)
(n = 20/605)
8.8%
(95% CI 5.9–11.7%)
72.7%
 (95% CI 48.9–96.5%)
Abbreviation: CI, confidence interval.
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which pyogenic streptococci were isolated, whereas the pro-
portion of lesions from which S. aureus was cultured did not 
change in either arm.
A major aim of scabies control programmes is a reduction in 
sequelae of S. pyogenes infection. Our study provides some of the 
first data demonstrating that the observed reduction in clinical 
impetigo may be due to a reduction in S. pyogenes infection. This 
decrease in pyogenic streptococci occurred in both communities 
that received ivermectin alone and those in which it was co-ad-
ministered with azithromycin. Why S. pyogenes should decline to 
a greater extent than S. aureus is unclear. Asymptomatic carriage 
of S. aureus is more common than carriage of S.pyogenes and can 
persist following MDA with azithromycin [17], so it might serve 
as a potential reservoir for ongoing transmission. Our data do 
not allow us to assess this hypothesis, and future studies to better 
understand the impact of MDA on impetigo lesions are warranted.
We observed an increase at 3  months in the proportion of 
strains of S. aureus that were macrolide resistant following MDA 
with azithromycin. This effect appeared to wane by 12 months 
post-MDA, although our sample size was too small to draw a 
firm conclusion on the duration of the effect. In the commu-
nities studied, there is limited use of macrolides other than in 
the management of sexually transmitted infections. The lack of 
ongoing selective pressure may have contributed to the return 
to a wild-type antibiotic susceptibility pattern at 12  months. 
Previous studies have demonstrated transient increases in the 
nasopharyngeal carriage of azithromycin resistant Streptococcus 
pneumoniae following azithromycin MDA, with limited evi-
dence that multiple rounds of MDA lead to greater selection 
of resistant isolates than a single round [14–16]. A  study of 
nasopharyngeal carriage of S.  aureus found macrolide resis-
tance increased within a month of azithromycin MDA but then 
declined over 6  months. Individuals who received multiple 
rounds of MDA were more likely to have resistant strains than 
those who had received only one round [17]. Collectively, these 
data highlight the need for ongoing vigilance concerning the 
impact of azithromycin MDA on organisms other than those 
that are the immediate target but also suggest that infrequent 
(annual) MDA of azithromycin is unlikely to substantially affect 
macrolide resistance rates in Gram-positive organisms [18].
Our study has several limitations. First, and consistent with 
other studies assessing the impact of MDA, it was not blinded. 
Second, the diagnosis of scabies and impetigo was made on 
clinical grounds alone, albeit by a single experienced physician 
using criteria that have previously been shown to have good 
sensitivity and specificity [27]. Third, follow-up rates differed 
between our 2 study arms. In one village in the ivermectin-only 
treatment arm, rumors circulated that MDA was being con-
ducted without approval from the local hospital even though 
hospital staff made up the majority of the field-team. Meetings 
were held with community leaders and the study team includ-
ing the hospital Director of Nursing (RA), but follow-up in this 
village remained lower than other villages in the study. Despite 
this, we had an adequate sample size to demonstrate that there 
was no additional reduction in impetigo prevalence in the arm 
receiving combined treatment, and our sensitivity analysis was 
consistent with our overall results. Fourth, we did not collect 
swabs from all individuals with active impetigo (nor from every 
lesion on individuals with multiple lesions). We cannot exclude 
the possibility that increasing the proportion of individuals from 
whom swabs were collected might have altered the proportion 
of samples containing pyogenic streptococci or macrolide-resis-
tant bacteria. Finally, samples were shipped to Australia, a jour-
ney that might also have reduced our pathogen recovery rate. 
However, we successfully isolated S. aureus, a streptococcus, or 
both from more than 95% of swabs so think it unlikely that the 
transport process affected our results. Our results are consis-
tent with previous studies on changing patterns of carriage of 
Table 4. Antimicrobial Sensitivity Testing Results
Baseline 3 Month 12 Months
Macrolide Resistant
(%, 95% CI)
Macrolide Resistant
(%, 95% CI)
Macrolide Resistant
(%, 95% CI)
Ivermectin only Staphylococcus aureus 0/27
(0%, 0–16%)
0/13
(0%, 0–28%)
0/6
(0%, 0–48%)
Pyogenic streptococcia 0/30
(0%, 0–14%)
0/9
(0%, 0–37%)
0/1
(0%, 0–95%)
Combined treatment Staphylococcus aureus 1/32
(3%, 0.2–18%)
8/15
(53%, 27–78%)
0/13
(0%, 0–28%)
Pyogenic streptococcia 0/19
(0%, 0–21%)
0/5
(0%, 0–54%)
0/4
(0%, 0–60%)
Total Staphylococcus aureus 1/59
(1.7%, 0–10%)
8/28
(29%, 14–49%)
0/19
(0%, 0–21%)
Pyogenic streptococcia 0/45
(0%, 0–13%)
0/14
(0%, 0–27%)
0/5
(0%, 0–54%)
Abbreviation: CI, confidence interval.
aFor simplicity we report Group C/G streptococci alongside S. pyogenes.
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antimicrobial resistant flora following MDA and provide some 
of the first bacteriological endpoint data on the impact of iver-
mectin MDA on impetigo.
Our data add to those from a small number of previous 
studies examining the potential of combining individual MDA 
programmes into a single intervention. Our study did not aim 
to investigate the safety of co-administration of ivermectin 
and azithromycin, as existing pharmacokinetic and trial data 
already support the safety of co-administration of these agents 
[25, 26], and we have recently completed a large scale field 
study directly addressing the question of safety at a district-level 
(ACTRN12613000474752) [37]. Although we were unable to 
detect any clinical impact on impetigo prevalence of adding azi-
thromycin to ivermectin MDA on impetigo prevalence, co-ad-
ministration still has potential logistical and financial benefits 
by treating multiple NTDs via a single intervention. Further 
studies on integrated approaches are needed to draw firmer 
conclusions about the potential benefit on disease occurrence.
Ivermectin MDA has emerged as a central component of the 
control strategy for scabies in high prevalence communities. 
Our data suggest the addition of a single dose of azithromycin, 
at a single timepoint, neither translates to an additional ben-
efit in reducing impetigo prevalence at 12 months nor results 
in an increased prevalence of antimicrobial resistance. It is not 
known whether alternative strategies, such as biannual MDA or 
use of an alternative antimicrobial agent, might be more suc-
cessful. Further investigation may help to optimize community 
interventions for the control of scabies and its sequelae.
Supplementary Data
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